Cullinan Oncology's Q2 earnings report shows a significant decrease in earnings per share compared to the same period last year, which could negatively impact investor sentiment and the stock price. However, the company's strong cash and investment position, which is expected to provide runway into 2026, may offset some of this negative impact.